The knock on the company is going stale: this quarter's own facts cut against the standing doubt
The model's full reasoning — Q1 2023 call → NO我们根据提供的财报电话会议记录,分析是否存在一个明确的、公司特定的疑虑,以及本季度的实际运营证据是否反驳了该疑虑。 首先,寻找疑虑。电话会议中,管理层多次提到“回归盈利”、“调整后EBITDA转正”等目标。分析师的问题也围绕增长、B2B波动、DTC生产力等。但最突出的疑虑似乎是公司能否实现盈利,以及增长是否可持续。管理层在开场就强调“回归盈利”和“调整后EBITDA在第四季度转正”。分析师Mike Matson问及第二季度收入,管理层只给出年度指引,暗示增长压力。分析师还问及B2B波动和DTC生产力。但更具体的疑虑可能是:公司能否摆脱亏损?管理层在回答中提到了“我们仍然专注于回归盈利,并预计在2023年第四季度实现调整后EBITDA为正”。这暗示投资者担心亏损持续。 然而,本季度的实际证据:管理层报告了收入符合预期,毛利率和EBITDA优于内部预期。DTC生产力提高(每代表单位数和收入均实现两位数增长),租赁收入增长25.4%,国内B2B增长146.7%(但基数低)。国际B2B下降,DTC下降。但管理层强调供应充足,且正在改善。关键的是,管理层说“我们继续看到对我们产品的潜在需求,并看到了可扩展和盈利增长的路径”。但这是否是实际证据?本季度净亏损仍为2030万美元,调整后EBITDA为负1180万美元。所以亏损仍在继续,但管理层说“优于内部预期”。然而,疑虑是能否盈利,而本季度仍然亏损,只是亏损幅度可能好于预期。但管理层说“我们预计在第四季度实现正调整后EBITDA”,这是预测,不是本季度事实。本季度实际证据是亏损,但管理层说“毛利率和EBITDA表现优于内部预期”,这暗示亏损收窄?但数字上,调整后EBITDA为负1180万,去年同期呢?没有给出去年同期调整后EBITDA,但总亏损为2030万,去年同期净亏损?从电话中,去年Q1净亏损?没有直接数据,但管理层说“总运营费用增加”,但收入下降。所以本季度亏损可能扩大?实际上,收入下降10.2%,运营费用增加,所以亏损可能扩大。但管理层说“毛利率和EBITDA表现优于内部预期”,可能指相对于内部预算,但实际仍是亏损。 疑虑是否明确?分析师问及“增长”和“B2B波动”,但更核心的疑虑可能是公司能否实现盈利。管理层在开场就强调“回归盈利”,这暗示投资者担心。但本季度实际证据是亏损,虽然管理层说优于预期,但并未扭亏。所以本季度证据并未反驳疑虑,反而可能确认疑虑(亏损持续)。但管理层说“我们预计第四季度转正”,这是未来计划。 另一个可能的疑虑:DTC业务下滑,但管理层说生产力提高,但实际DTC收入下降29.2%。所以疑虑可能是DTC能否恢复增长?但本季度DTC收入下降,虽然生产力提高,但总体下降。所以证据并未反驳。 再考虑B2B波动,但本季度国内B2B增长146%,但基数低,且管理层说“软启动”,所以可能波动。 最明显的疑虑可能是“公司能否实现盈利”,因为管理层反复强调“回归盈利”和“调整后EBITDA转正”。但本季度仍然亏损,所以证据并未反驳,反而可能支持疑虑。但管理层说“毛利率和EBITDA表现优于内部预期”,这暗示亏损幅度小于预期,但仍是亏损。所以没有明确反驳。 另一个疑虑:供应问题?管理层说供应改善,但本季度收入下降,但管理层说不是供应问题。所以供应疑虑被反驳?但供应疑虑是过去的,现在说供应充足,但本季度收入下降,所以可能需求问题。 我认为没有明确的、公司特定的疑虑被本季度实际证据反驳。管理层主要用未来计划回应,而不是本季度事实。例如,关于盈利,管理层说“我们预计第四季度转正”,这是预测。关于DTC,管理层说“生产力提高”,但收入下降。所以证据并未明确反驳。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| PRA | ProAssurance Corporation | Q1 2024 | 2024-05-11 | D |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| BXSL | Blackstone Secured Lending Fund | Q1 2023 | 2023-05-10 | A |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CLSD | Clearside Biomedical, Inc. | Q3 2022 | 2022-11-09 | C |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| STC | Stewart Information Services Corporation | Q1 2022 | 2022-04-29 | C+ |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| ULBI | Ultralife Corporation | Q3 2016 | 2016-10-29 | C+ |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.